
    
      HU or placebo is added 30-60 days after the initiation of DMP, ddI, and d4T combination
      therapy. Patients are stratified according to antiretroviral experience (naive or
      experienced). Patients are followed for 48 weeks to determine safety, efficacy, and effect of
      treatment on viral, immunologic,and biochemical parameters.
    
  